ArticleMolecular biology reports2025
Identification of a novel nonsense mutation in the AGL gene in glycogen storage disease type IIIa: first genetically confirmed case report from Morocco.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycogen storage disease type III (GSD III) is an autosomal recessive disorder caused by mutations in the AGL gene, leading to a deficiency of the glycogen debranching enzyme. It is characterized by heterogeneous clinical and genetic presentations, with limited data available from North Africa. In the present study, we report a novel AGL variant in GSD III. A 20-month-old boy presented with hepatomegaly, fasting hypoglycemia and elevated transaminases. Hepatic biopsy revealed hepatocyte enlargement with glycogen accumulation and a 12-hour urine sample analyzed by thin-layer chromatography revealed the tetrasaccharide (glucose)₄ excretion. Next-generation sequencing identified a novel nonsense variant in exon 31 of the AGL gene NM_000642.3:c.4223T > A, p.(Leu1408*). This variant, absent from international databases, represents the first genetically confirmed GSD III case in Morocco. Despite dietary management, the patient developed respiratory distress and died before age three. DISCUSSION: This study outlines the genetic and phenotypic features of a Moroccan GSD III patient and describes a novel AGL variant that broadens the mutational spectrum. The severe outcome likely reflects the combination of its truncating nature, homozygous state, and critical location in exon 31, within the glycogen-binding domain. As reported, this association has been linked to early cardiomyopathy, poor dietary response, and increased risk of sudden death.
conclusionsGSD III is underdiagnosed in Morocco, which is concerning, as patients with GSD III can achieve significant improvement with appropriate dietary management. Indeed, timely diagnosis and treatment, can greatly benefit patients and even lead to partial recovery and guide family screening and counseling.
Indexed as
Identifiers
41389110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.